Delcath updated logo 2022 770x500Delcath Systems (Nasdaq:DCTH) announced today that its board of directors voted to appoint John R. Sylvester as its new chair.

Sylvester joined Delcath as a director in July 2019. He currently serves as CEO of Curium Pharma’s SPECT and international businesses. Previously, Sylvester served as BTG’s chief commercial officer, leading the company’s interventional oncology and interventional vascular businesses.

He brings extensive experience building interventional oncology businesses, Delcath said in a news release. This includes his work at BTG before Boston Scientific bought it for $4.2 billion. Sylvester also built Biocompatibles International’s interventional oncology business, which BTG bought in 2010.

“I look forward to partnering with John in his new role and know that the company will greatly benefit from his extensive experience in commercializing innovative interventional oncology products, as we prepare for launch in the U.S.,” Delcath CEO Gerard Michel said in the release.

Dr. Roger Stoll, who served as Delcath’s chair since October 2015, continues to serve as an active member of the board. He labeled Sylvester “ideally suited” to take the Delcath board chair role.

Sylvester thanked Stoll for his leadership during Delcath’s Focus trial for its Hepzato therapy. Delcath’s therapy is a percutaneous targeted, whole-organ treatment that delivers a select high-dose chemotherapy agent directly to the liver.

“The Hepzato Kit is a truly unique interventional oncology product which, if approved, will offer unique advantages to healthcare professionals and patients and I look forward to guiding the company through its planned growth,” Sylvester said.